Janux Therapeutics, Inc. (JANX) is a publicly traded company in the Unknown sector. Across all available filings, 26 corporate insiders have executed 159 transactions totaling $409.1M, demonstrating a bearish sentiment with -$152.7M in net insider flow. The most recent transaction on Feb 2, 2026 involved a transaction of 154,000 shares valued at $0.
No significant insider buying has been recorded for JANX in the recent period.
No significant insider selling has been recorded for JANX in the recent period.
Based on recent SEC filings, insider sentiment for JANX is bearish with an Insider Alignment Score of 31/100 and a net flow of -$152.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Janux Therapeutics, Inc. (JANX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 26 insiders are actively trading JANX stock, having executed 159 transactions in the past 90 days. The most active insider is Jay Lichter (Executive), who has made 11 transactions totaling $97.8M.
Get notified when executives and directors at JANX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Go William | Chief Medical Officer | Award | 154,000 | $N/A | $0 | |
| Feb 2, 2026 | Go William | Chief Medical Officer | Award | 44,000 | $N/A | $0 | |
| Jan 2, 2026 | Dobek Maria | Vice President, Accounting | Award | 42,600 | $N/A | $0 | |
| Jan 2, 2026 | Dobek Maria | Vice President, Accounting | Award | 18,935 | $N/A | $0 | |
| Jan 2, 2026 | Dobek Maria | Vice President, Accounting | Sale | 1,462 | $13.73 | $20.1K | |
| Jan 2, 2026 | Noel Doyle Janeen | Chief Corp. & Bus. Dev. Ofcr | Award | 126,000 | $N/A | $0 | |
| Jan 2, 2026 | Noel Doyle Janeen | Chief Corp. & Bus. Dev. Ofcr | Award | 36,000 | $N/A | $0 | |
| Jan 2, 2026 | Mciver Zachariah | Chief Medical Officer | Award | 101,500 | $N/A | $0 | |
| Jan 2, 2026 | Mciver Zachariah | Chief Medical Officer | Award | 29,000 | $N/A | $0 | |
| Jan 2, 2026 | Mciver Zachariah | Chief Medical Officer | Sale | 2,714 | $13.73 | $37.3K | |
| Jan 2, 2026 | M. Winter Charles | Chief Technical Officer | Award | 100,100 | $N/A | $0 | |
| Jan 2, 2026 | M. Winter Charles | Chief Technical Officer | Award | 28,600 | $N/A | $0 | |
| Jan 2, 2026 | M. Winter Charles | Chief Technical Officer | Sale | 2,401 | $13.73 | $33.0K | |
| Jan 2, 2026 | Alan Campbell David | Executive | Award | 338,100 | $N/A | $0 | |
| Jan 2, 2026 | Alan Campbell David | Executive | Award | 96,600 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 63 | $280.9M | 68.6% |
Purchase(P) | 14 | $128.2M | 31.3% |
Exercise(M) | 17 | $479.9K | 0.1% |
Award(A) | 28 | $0 | 0.0% |
Other(J) | 11 | $0 | 0.0% |
Conversion(C) | 26 | $0 | 0.0% |
Insider selling pressure at Janux Therapeutics, Inc. has increased, with 26 insiders executing 159 transactions across all time. Total sales of $280.9M significantly outpace purchases of $128.2M, resulting in a net outflow of $152.7M. This selling activity appears largely discretionary, which may warrant closer attention from investors.